Retinoic acid upregulates the plasminogen activator system in human epidermal keratinocytes

Journal of Investigative Dermatology

Volumn 116, Issue 5, 2001, Pages 778-784

  Braungart, Evelyn ^a   Magdolen, Viktor ^b   Degitz, Klaus ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Epithelialization; Keratinocyte; Plasminogen activator system; Retinoic acid; Wound healing

Indexed keywords

CHROMOGENIC SUBSTRATE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; RETINOIC ACID; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMIS; EPITHELIZATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KERATINOCYTE; NORMAL HUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 0035008953     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2001.01310.x     Document Type: Article

References (57)

1. Anthony J, Miller L, Dinehart SM: Topical tretinoin decreases healing times of electroepilation-induced wounds. Dermatologica 183:129-131, 1991
2. Arboleda B, Cruz NI: The effect of systemic isotretinoin on wound contraction in guinea pigs. Plast Reconstr Surg 83:118-121, 1989
3. Bachmann F: The enigma PAI-2. Gene expression, evolutionary and functional aspects. Thromb Haemost 74:172-179, 1995
4. Baird J, Lazarus GS, Belin D, Vassalli JD, Busso N, Gubler P, Jensen PJ: MRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis. J Invest Dermatol 95:548-552, 1990
5. Behrends U, Peter RU, Hintermeier-Knabe R, et al: Ionizing irradiation induces human intercellular adhesion molecule-1 in vitro. J Invest Dermatol 103:726-730, 1994
6. Blasi F: UPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 18:415-417, 1997
7. Brown JM, Cohen RL, Chambers DA: Effects of retinoic acid on plasminogen activators in murine epidermal cell culture. Ann N Y Acad Sci 667:50-51, 1992
8. Bugge TH, Flick MJ, Danton MJ, et al: Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 93:5899-5904, 1996
9. Bulens F, Ibanez Tallon I, Van Acker P, De Vriese A, Nelles L, Belayew A, Collen D: Retinoic acid induction of human tissue-type plasminogen activator gene expression via a direct repeat element (DR5) located at -7 kilobases. J Biol Chem 270:7167-7175, 1995
10. Carmeliet P, Schoonjans L, Kieckens L, et al: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368:419-424, 1994
11. Clark RAF. Mechanisms of cutaneous wound repair. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB (eds). Dermatology in General Medicine, 4th edn. New York: McGraw-Hill, 1999, pp. 326-341
12. Gille J, Paxton LLL, Lawley TJ, Caughman SW, Swerlick RA: Retinoic acid inhibits the regulated expression of vascular cell adhesion molecule 1 by cultured dermal microvascular endothelial cells. J Clin Invest 99:492-500, 1997
13. Gonzalez IL, Gorski JL, Campen TJ, Dorney DJ, Erickson JM, Sylvester JE, Schmickel RD: Variation among human 28S ribosomal RNA genes. Proc Natl Acad Sci USA 82:7666-7670, 1985
14. Grondahl-Hansen J, Lund LR, Ralfkiaer E, Ottevanger V, Dano K: Urokinase-and tissue-type plasminogen activators in keratinocytes during wound re-epithelialization in vivo. J Invest Dermatol 90:790-795, 1988
15. Hakkinen L, Westermarck J, Johansson N, Aho H, Peltonen J, Heino J, Kahari VM: Suprabasal expression of epidermal alpha 2 beta 1 and alpha 3 beta 1 integrins in skin treated with topical retinoic acid. Br J Dermatol 138:29-36, 1998
16. Hertle MD, Kubler MD, Leigh IM, Watt FM: Aberrant integrin expression during epidermal wound healing and in psoriatic epidermis. J Clin Invest 89:1892-1901, 1992
17. Hevia O, Nemeth AJ, Taylor JR: Tretinoin accelerates healing after trichloroacetic acid chemical peel. Arch Dermatol 127:678-682, 1991
18. Hung VC, Lee JY, Zitelli JA, Hebda PA: Topical tretinoin and epithelial wound healing. Arch Dermatol 125:65-69, 1989
19. Jensen PJ, Lavker RM: Modulation of the plasminogen activator cascade during enhanced epidermal proliferation in vivo. Cell Growth Differ 7:1793-1804, 1996
20. Jensen PJ, Baird J, Morioka S, Lessin S, Lazarus GS: Epidermal plasminogen activator is abnormal in cutaneous lesions. J Invest Dermatol 90:777-782, 1988
21. Jensen PJ, Wu Q, Janowitz P, Ando Y, Schechter NM: Plasminogen activator inhibitor type 2: an intracellular keratinocyte differentiation product that is incorporated into the cornified envelope. Exp Cell Res 217:65-71, 1995
22. Jimenez PA, Teliska M, Liu B, Antonnacio MJ: Urokinase-type plasminogen activator stimulates wound healing in the diabetic mouse. Inflamm Res 46(Suppl. 2):S169-S170, 1997
23. Kang S, Voorhees JJ. Topical retinoids. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB (eds). Dermatology in General Medicine, 4th edn. New York: McGraw-Hill, 1999: pp 2726-2733
24. Kligman AM, Grove GL, Hirose R, Leyden JJ: Topical tretinoin for photoaged skin. J Am Acad Dermatol 15:836-859, 1986
25. Kramer MD, Schaefer B, Reinartz J: Plasminogen activation by human keratinocytes: molecular pathways and cell-biological consequences. Biol Chem Hoppe-Seyler 376:131-141, 1995
26. Larjava H, Salo T, Haapasalmi K, Kramer RH, Heino J: Expression of integrins and basement membrane components by wound keratinocytes. J Clin Invest 92:1425-1435, 1993
27. Leyland H, Gentry J, Arthur MJ, Benyon RC: The plasminogen-activating system in hepatic stellate cells. Hepatology 24:1172-1178, 1996
28. Lyons-Giordano B, Loskutoff D, Chen CS, Lazarus G, Keeton M, Jensen PJ: Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochemistry 101:105-112, 1994
29. Mandy SH: Tretinoin in the preoperative and postoperative management of dermabrasion. J Am Acad Dermatol 15:878-879, 1986
30. Marschall C, Lengyel E, Nobutoh T, et al: UVB increases urokinase-type plasminogen activator receptor (uPAR) expression. J Invest Dermatol 113:77-81, 1999
31. Martin P: Wound healing - aiming for perfect skin regeneration. Science 276:75-81, 1997
32. Mira-Y-Lopez R, Jaramillo S, Jing Y: Synergistic transcriptional activation of the mouse urokinase plasminogen activator (uPA) gene and of its enhancer activator protein 1 (AP1) site by cAMP and retinoic acid. Biochem J 331:909-916, 1998
33. Muehlenweg B, Guthaus E, De Prada NA, et al: Epitope mapping of monoclonal antibodies directed to PAI-1 using PAI-1/PAI-2 chimera and PAI-1-derived synthetic peptides. Thromb Res 98:73-81, 2000
34. Pfahl M: Nuclear receptor/AP-1 interaction. Endocr Rev 14:651-658, 1993
35. Popp C, Kligman AM, Stoudemayer TJ: Pretreatment of photoaged forearm skin with topical tretinoin accelerates healing of full-thickness wounds. Br J Dermatol 132:46-53, 1995
36. Reinartz J, Schaefer B, Bechtel MJ, Kramer MD: Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator. Exp Cell Res 223:91-101, 1996
37. Reuning U, Wilhelm O, Nishiguchi T, Guerrini L, Blasi F, Graeff H, Schmitt M: Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxy-nucleotides suppresses synthesis of urokinase-cype plasminogen activator (uPA) but not its inhibitor PAI-1. Nucleic Acids Res 23:3887-3893, 1995
38. Risse BC, Chung NM, Baker MS. Jensen P: Evidence for intracellular cleavage of plasminogen activator inhibitor type 2 (PAI-2) in normal epidermal keratinocytes. J Cell Physiol 182:281-289, 2000
39. Roldan AL, Cubellis MV, Masucci MT, et al: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9:467-474, 1990
40. Romer J, Lund LR, Eriksen J, Pyke C, Kristensen P, Dano K: The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. J Invest Dermatol 102:519-522, 1994
41. Romer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, Dano K: Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 2:287-292, 1996
42. Rubenstein R, Roenigk HH Jr, Stegman SJ, Hanke CW: Atypical keloids after dermabrasion of patients taking isotretinoin. J Am Acad Dermatol 15:280-285, 1985
43. Schmalfeldt B, Kuhn W, Reuning U, et al: Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res 55:3958-3963, 1995
44. Schmitt M, Wilhelm O. Jänicke F, et al: Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. J Obst Gynecol 21:151-165, 1995
45. Schott D, Dempfle CE, Beck P, et al: Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. N Engl J Med 339:1679-1686, 1998
46. Schroen DJ, Brinckerhoff CE: Inhibition of rabbit collagenase (matrix metalloproteinase-1; MMP-1) transcription by retinoid receptors: evidence for binding of RARs/RXRs to the -77 AP-1 site through interactions with c-Jun. J Cell Physiol 169:320-332, 1996
47. Stürzebecher J, Vieweg H, Steinmetzer T, Schweinitz A, Stubbs MT, Renatus M, Wilkstrom P: 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg Med Chem Lett 9:3147-3152, 1999
48. Suzuki Y, Shimada J, Shudo K, Matsumura M, Crippa MP, Kojima S: Physical interaction between retinoic acid receptor and Sp1: mechanism for induction of urokinase by retinoic acid. Blood 93:4264-4276, 1999
49. Thompson EA, Nelles L, Collen D: Effect of retinoic acid on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in human endothelial cells. Eur J Biochem 201:627-632, 1991
50. Todd R, Magdolen V, Cines D, et al: CD87 Workshop Panel report. In: Kishimoto T (ed.) Leukocyte typing VI. London: Garland Press, 1997: pp 1016-1020
51. Tsuboi R, Sato C, Kurita Y, Ron D, Rubin JS, Ogawa H: Keratinocyte growth factor (FGF-7) stimulates migration and plasminogen activator activity of normal human keratinocytes. J Invest Dermatol 101:49-53, 1993
52. Turkmen B, Schmitt M, Schmalfeldt B. et al: Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer. Electrophoresis 18:686-689, 1997
53. Varani J, Nickoloff BJ, Dixit VM, Mitra RS, Voorhees JJ: All-trans retinoic acid stimulates growth of adult human keratinocytes cultured in growth factor-deficient medium, inhibits production of thrombospondin and fibronectin, and reduces adhesion. J Invest Dermatol 93:449-454, 1989
54. Varani J, Burmeister B, Sitrin RG, et al: Expression of serine proteinases and metalloproteinases in organ-cultured human skin. Altered levels in the presence of retinoic acid and possible relationship to retinoid-induced loss of epidermal cohesion. Am J Pathol 145:561-573, 1994
55. Varani J, Perone P, Inman DR, et al: Human skin in organ culture. Elaboration of proteolytic enzymes in the presence and absence of exogenous growth factors. Am J Pathol 146:210-217, 1995
56. Watcher MA, Wheeland RG: The role of topical agents in the healing of full-thickness wounds. J Dermatol Surg Oncol 15:1188-1195, 1989
57. Zachariae H: Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment. Br J Dermatol 118:703-706, 1988 treatment or dermabrasion during isotretinoin treatment